Treatment of anemia in patients with chronic heart failure

Stuart D. Katz, Donna Mancini, Ana Silvia Androne, Katarzyna Hryniewicz

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Anemia is common in heart failure patients and is associated with increased mortality risk. Anemia is multifactorial in etiology and is likely related to the actions of proinflammatory cytokines with consequent reduced red blood cell production and hemodilution secondary to plasma volume expansion. Hemodynamic consequences of anemia may contribute to the progression of heart failure symptoms and ventricular remodeling. Treatment trials with recombinant human erythropoietin in patients with end-stage renal disease and concomitant structural heart disease have demonstrated beneficial effects on cardiac remodeling but variable effects on clinical outcome. Preliminary trials in patients with chronic heart failure demonstrate that erythropoietin therapy is well-tolerated and associated with short-term clinical benefits. Additional studies are needed to investigate the effects of long-term erythropoietic therapy on clinical outcomes.

Original languageEnglish
Pages (from-to)221-224
Number of pages4
JournalEuropean Journal of Heart Failure, Supplement
Issue number2
StatePublished - Jun 2003
Externally publishedYes


  • Blood volume
  • Erythropoietin
  • Heart failure
  • Plethysmography
  • Vascular resistance


Dive into the research topics of 'Treatment of anemia in patients with chronic heart failure'. Together they form a unique fingerprint.

Cite this